Robert B. Carter has reported the acquisition of 10 shares of Quest Diagnostics, Inc. This transaction, filed on October 23, 2026, is significant as it increases Carter's total ownership to 3,874 shares of the company.
This acquisition is noteworthy not only for Carter but also for Quest Diagnostics, a leader in the medical laboratory services industry. The transaction comes at a time when the company is navigating a competitive landscape, which includes various players in the sector.
Background
Quest Diagnostics Inc, identified by the Central Index Key (CIK) 0001022079, operates within the medical laboratories sector, classified under the SIC code 8071. The company is headquartered in Secaucus, New Jersey, and is publicly traded. Its fiscal year ends on December 31.
What the Filing Says
According to the SEC filing, the transaction took place on October 21, 2026, with shares acquired at a price of $235.93 each. The filing states: "Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4." This indicates that Carter is actively engaged in managing his investment portfolio.
Impact
This acquisition may influence other stakeholders and investors in Quest Diagnostics, as it demonstrates an ongoing commitment from a key individual in the company. The medical laboratory services sector remains competitive, and such transactions can signal confidence in the company's direction and performance.
What's Next
The filing does not say what happens next.